Five Prime Enters Transition Phase; Multiple Trials Planned In Next 12 Months
Five Prime, in partnership with immunotherapy giant Bristol-Myers Squibb, will launch several pivotal trials in the next 12 months for its lead compound cabiralizumab – both in combination with Opdivo in cancer and as a monotherapy in orphan disease PVNS.
You may also be interested in...
Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.